Sarcoma,Soft Tissue
46
18
26
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.2%
1 terminated out of 46 trials
92.9%
+6.4% vs benchmark
7%
3 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (46)
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma (SPARE-01)
Pemetrexed, Cisplatin With Soft Tissue Sarcoma
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)
GISAR German Interdisciplinary Sarcoma Registry
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma (SPARE-02)
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial
Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery
BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers